Credit: Shutterstock photoPresident and CEO of Aevi Genomic Medicine Inc ( GNMX ) Michael F Cola bought 119,047 shares of GNMX on 10/17/2017 at an average price of $1.26 a share. The total cost of this purchase was $149,999.
Aevi Genomic Medicine Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases. Aevi Genomic Medicine Inc has a market cap of $47.510 million; its shares were traded at around $1.28 . Aevi Genomic Medicine Inc had annual average EBITDA growth of 5.30% over the past five years.
CEO Recent Trades:
- President and CEO Michael F Cola bought 119,047 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
Directors and Officers Recent Trades:
- Director Eugene A Bauer bought 19,841 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
- Director Alastair J Clemow bought 19,841 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
- Director Barbara Gayle Duncan bought 59,524 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
- Director Wilbur H Gantz bought 39,683 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
- Chief Scientific Officer Garry Arthur Neil bought 75,000 shares of GNMX stock on 10/17/2017 at the average price of $1.26. The price of the stock has increased by 1.59% since.
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
